Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 35 | 2023 | 222 | 12.850 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 24 | 2023 | 149 | 6.700 |
Why?
|
| Pulmonary Fibrosis | 11 | 2023 | 117 | 5.620 |
Why?
|
| Alveolitis, Extrinsic Allergic | 9 | 2022 | 33 | 2.610 |
Why?
|
| Lung | 17 | 2023 | 1124 | 2.070 |
Why?
|
| Mucin-5B | 4 | 2022 | 11 | 1.700 |
Why?
|
| Telomere | 6 | 2023 | 104 | 1.430 |
Why?
|
| Lung Transplantation | 4 | 2023 | 173 | 1.410 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2023 | 2497 | 1.390 |
Why?
|
| Pyridones | 2 | 2020 | 49 | 1.340 |
Why?
|
| Connective Tissue Diseases | 8 | 2023 | 65 | 1.320 |
Why?
|
| Indoles | 2 | 2020 | 315 | 1.190 |
Why?
|
| Idiopathic Interstitial Pneumonias | 4 | 2022 | 28 | 1.160 |
Why?
|
| Hospitalization | 4 | 2021 | 809 | 1.150 |
Why?
|
| Humans | 71 | 2023 | 83922 | 1.090 |
Why?
|
| Disease Progression | 11 | 2023 | 1478 | 1.060 |
Why?
|
| Fibrosis | 6 | 2023 | 194 | 1.000 |
Why?
|
| Pulmonary Emphysema | 1 | 2023 | 26 | 0.950 |
Why?
|
| Emphysema | 1 | 2023 | 19 | 0.950 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1636 | 0.910 |
Why?
|
| Nitric Oxide | 2 | 2022 | 275 | 0.910 |
Why?
|
| Cohort Studies | 12 | 2023 | 2703 | 0.890 |
Why?
|
| Delayed Diagnosis | 2 | 2019 | 28 | 0.890 |
Why?
|
| Aged | 31 | 2023 | 18102 | 0.890 |
Why?
|
| Mediastinum | 2 | 2019 | 46 | 0.890 |
Why?
|
| Autoimmunity | 4 | 2018 | 155 | 0.880 |
Why?
|
| Rheumatoid Factor | 1 | 2021 | 24 | 0.870 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 16 | 0.860 |
Why?
|
| Mediastinal Diseases | 1 | 2021 | 20 | 0.860 |
Why?
|
| Intra-Abdominal Fat | 1 | 2021 | 30 | 0.840 |
Why?
|
| Friends | 1 | 2021 | 14 | 0.820 |
Why?
|
| Immunosuppressive Agents | 5 | 2019 | 967 | 0.800 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2021 | 153 | 0.780 |
Why?
|
| Radiography, Thoracic | 3 | 2019 | 320 | 0.770 |
Why?
|
| Autoimmune Diseases | 3 | 2017 | 231 | 0.760 |
Why?
|
| Hypertension, Pulmonary | 5 | 2022 | 332 | 0.760 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2020 | 51 | 0.740 |
Why?
|
| Racism | 1 | 2021 | 76 | 0.740 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2020 | 203 | 0.740 |
Why?
|
| Mortality | 1 | 2020 | 148 | 0.730 |
Why?
|
| Male | 36 | 2023 | 40248 | 0.720 |
Why?
|
| Retrospective Studies | 20 | 2023 | 8073 | 0.700 |
Why?
|
| Patient Compliance | 1 | 2020 | 220 | 0.690 |
Why?
|
| Lymph Nodes | 2 | 2019 | 527 | 0.670 |
Why?
|
| Pandemics | 2 | 2021 | 693 | 0.650 |
Why?
|
| Prognosis | 9 | 2023 | 3617 | 0.640 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 264 | 0.630 |
Why?
|
| Betacoronavirus | 1 | 2020 | 253 | 0.630 |
Why?
|
| Female | 34 | 2023 | 43770 | 0.620 |
Why?
|
| Pathology, Clinical | 1 | 2017 | 32 | 0.620 |
Why?
|
| Multiple Chronic Conditions | 1 | 2016 | 5 | 0.610 |
Why?
|
| Middle Aged | 25 | 2021 | 24698 | 0.570 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 310 | 0.540 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 295 | 0.540 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 147 | 0.530 |
Why?
|
| Polymorphism, Genetic | 1 | 2019 | 817 | 0.530 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2015 | 97 | 0.510 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 237 | 0.500 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2015 | 129 | 0.500 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 632 | 0.470 |
Why?
|
| Aortic Valve Stenosis | 2 | 2011 | 121 | 0.460 |
Why?
|
| Leukocytes | 3 | 2023 | 200 | 0.450 |
Why?
|
| Minority Groups | 2 | 2023 | 127 | 0.430 |
Why?
|
| Risk Assessment | 6 | 2021 | 2223 | 0.420 |
Why?
|
| Biomarkers | 4 | 2021 | 1657 | 0.420 |
Why?
|
| Respiratory Function Tests | 5 | 2023 | 133 | 0.420 |
Why?
|
| United States | 8 | 2023 | 6428 | 0.410 |
Why?
|
| Prevalence | 7 | 2021 | 1218 | 0.410 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 2232 | 0.400 |
Why?
|
| Survival Analysis | 4 | 2019 | 1531 | 0.390 |
Why?
|
| Hypoxia | 1 | 2015 | 621 | 0.370 |
Why?
|
| Inflammation | 1 | 2015 | 875 | 0.360 |
Why?
|
| Quality of Life | 1 | 2016 | 1504 | 0.340 |
Why?
|
| Survival Rate | 4 | 2020 | 1843 | 0.340 |
Why?
|
| Proportional Hazards Models | 4 | 2023 | 852 | 0.320 |
Why?
|
| Cause of Death | 2 | 2019 | 273 | 0.320 |
Why?
|
| Echocardiography | 2 | 2022 | 893 | 0.320 |
Why?
|
| Registries | 5 | 2022 | 688 | 0.300 |
Why?
|
| Genome-Wide Association Study | 3 | 2023 | 1566 | 0.300 |
Why?
|
| Postoperative Complications | 1 | 2016 | 2196 | 0.290 |
Why?
|
| Heart Failure | 1 | 2015 | 1153 | 0.290 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 922 | 0.280 |
Why?
|
| Adult | 9 | 2023 | 25204 | 0.260 |
Why?
|
| Phenotype | 3 | 2020 | 2323 | 0.250 |
Why?
|
| Telomerase | 2 | 2020 | 53 | 0.240 |
Why?
|
| Tobacco Smoking | 1 | 2023 | 23 | 0.240 |
Why?
|
| Biopsy | 4 | 2021 | 1139 | 0.230 |
Why?
|
| Age Factors | 3 | 2020 | 1823 | 0.230 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 1753 | 0.230 |
Why?
|
| Risk Factors | 3 | 2021 | 5301 | 0.210 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 980 | 0.210 |
Why?
|
| Survivors | 1 | 2023 | 217 | 0.210 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 28 | 0.200 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2021 | 92 | 0.200 |
Why?
|
| Respiratory Mucosa | 1 | 2021 | 86 | 0.200 |
Why?
|
| Health Services | 1 | 2021 | 56 | 0.200 |
Why?
|
| Occupational Health | 1 | 2021 | 32 | 0.200 |
Why?
|
| Hematology | 1 | 2020 | 29 | 0.200 |
Why?
|
| Vital Capacity | 4 | 2022 | 62 | 0.190 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 71 | 0.190 |
Why?
|
| Diagnosis, Differential | 4 | 2018 | 1535 | 0.190 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 375 | 0.190 |
Why?
|
| Occupational Exposure | 1 | 2021 | 79 | 0.190 |
Why?
|
| Telomere-Binding Proteins | 1 | 2019 | 14 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2023 | 4091 | 0.190 |
Why?
|
| Mutation | 3 | 2020 | 3889 | 0.190 |
Why?
|
| Myeloblastin | 1 | 2019 | 5 | 0.180 |
Why?
|
| Killer Cells, Natural | 1 | 2021 | 264 | 0.180 |
Why?
|
| Peroxidase | 1 | 2019 | 51 | 0.180 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2019 | 21 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 328 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2019 | 95 | 0.170 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 988 | 0.170 |
Why?
|
| Influenza, Human | 1 | 2021 | 336 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 383 | 0.160 |
Why?
|
| Free Radical Scavengers | 1 | 2018 | 58 | 0.160 |
Why?
|
| Genotype | 2 | 2022 | 1831 | 0.160 |
Why?
|
| Propensity Score | 1 | 2018 | 139 | 0.160 |
Why?
|
| Anticoagulants | 1 | 2021 | 399 | 0.160 |
Why?
|
| Bronchiectasis | 1 | 2017 | 12 | 0.160 |
Why?
|
| Time Factors | 3 | 2021 | 5176 | 0.160 |
Why?
|
| Acetylcysteine | 1 | 2018 | 69 | 0.160 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2017 | 18 | 0.160 |
Why?
|
| Interleukin-5 | 1 | 2017 | 36 | 0.160 |
Why?
|
| Sex Factors | 1 | 2020 | 1038 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2017 | 950 | 0.160 |
Why?
|
| Transcriptome | 1 | 2021 | 546 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2019 | 321 | 0.150 |
Why?
|
| Cluster Analysis | 1 | 2017 | 363 | 0.150 |
Why?
|
| Acute Lung Injury | 1 | 2017 | 60 | 0.150 |
Why?
|
| Disease Management | 2 | 2016 | 323 | 0.150 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 72 | 0.150 |
Why?
|
| Azathioprine | 1 | 2016 | 123 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2021 | 573 | 0.140 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 14 | 0.140 |
Why?
|
| Hypoventilation | 1 | 2015 | 6 | 0.140 |
Why?
|
| STAT6 Transcription Factor | 1 | 2015 | 27 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2017 | 458 | 0.130 |
Why?
|
| Carrier Proteins | 1 | 2018 | 662 | 0.130 |
Why?
|
| Antigens | 1 | 2016 | 224 | 0.130 |
Why?
|
| Comorbidity | 2 | 2017 | 933 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 151 | 0.130 |
Why?
|
| Logistic Models | 1 | 2018 | 1157 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 372 | 0.130 |
Why?
|
| rho-Associated Kinases | 1 | 2015 | 159 | 0.130 |
Why?
|
| Genomics | 1 | 2019 | 679 | 0.130 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 230 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 1 | 2015 | 276 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 321 | 0.120 |
Why?
|
| Sleep Wake Disorders | 1 | 2015 | 111 | 0.120 |
Why?
|
| Environmental Exposure | 1 | 2016 | 280 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 255 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2015 | 259 | 0.120 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 6453 | 0.110 |
Why?
|
| Canada | 2 | 2023 | 202 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2015 | 442 | 0.110 |
Why?
|
| Child | 1 | 2023 | 6709 | 0.110 |
Why?
|
| Autopsy | 2 | 2021 | 109 | 0.100 |
Why?
|
| Cytokines | 1 | 2015 | 754 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1033 | 0.100 |
Why?
|
| Treatment Outcome | 2 | 2019 | 7778 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2020 | 3180 | 0.090 |
Why?
|
| Obesity | 1 | 2015 | 939 | 0.080 |
Why?
|
| Antibodies, Antinuclear | 2 | 2018 | 83 | 0.080 |
Why?
|
| Cell Cycle Proteins | 2 | 2020 | 380 | 0.080 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2011 | 506 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 2222 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1786 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 854 | 0.060 |
Why?
|
| Proprotein Convertases | 1 | 2023 | 26 | 0.060 |
Why?
|
| Australasia | 1 | 2023 | 4 | 0.060 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2023 | 48 | 0.060 |
Why?
|
| Lung Volume Measurements | 1 | 2022 | 19 | 0.060 |
Why?
|
| Serine Endopeptidases | 1 | 2023 | 145 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1967 | 0.060 |
Why?
|
| Europe | 1 | 2023 | 304 | 0.060 |
Why?
|
| North America | 1 | 2023 | 174 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2022 | 62 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 2652 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2021 | 303 | 0.050 |
Why?
|
| Biology | 1 | 2020 | 45 | 0.050 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2020 | 8 | 0.050 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2020 | 11 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2020 | 22 | 0.050 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 15 | 0.050 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2020 | 7 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2019 | 8 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2020 | 56 | 0.050 |
Why?
|
| Spindle Apparatus | 1 | 2020 | 63 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 348 | 0.050 |
Why?
|
| Seasons | 1 | 2021 | 239 | 0.050 |
Why?
|
| Vasculitis | 1 | 2019 | 38 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 62 | 0.040 |
Why?
|
| Animals | 2 | 2017 | 26006 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2019 | 76 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 342 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 280 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 181 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 455 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2021 | 313 | 0.040 |
Why?
|
| Bleomycin | 1 | 2017 | 97 | 0.040 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 23 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2023 | 2322 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 103 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1738 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2016 | 85 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2017 | 145 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1536 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 233 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 396 | 0.030 |
Why?
|
| RNA | 1 | 2019 | 539 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2017 | 293 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 1276 | 0.030 |
Why?
|
| Observer Variation | 1 | 2017 | 594 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2019 | 692 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2016 | 462 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 422 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2017 | 1884 | 0.030 |
Why?
|
| Chicago | 1 | 2017 | 1361 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2019 | 1351 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2763 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 3025 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2186 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 1889 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 5844 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 10931 | 0.010 |
Why?
|